Financials

	2024	2025
Net sales	4.05Cr 4.54Cr 3.77Cr 3.43Cr 6.46Cr 437.09Cr 6.51Cr 46Cr 18Cr 223.08Cr 17Cr 17Cr 717.07Cr	4.11Cr 4.61Cr 3.83Cr 3.48Cr 6.56Cr 443.68Cr 6.61Cr 46Cr 18Cr 226.45Cr 17Cr 17Cr 727.89Cr
Net income	71.55L 80.2L 66.65L 60.66L 1.14Cr 77Cr 1.15Cr 8.05Cr 3.13Cr 39Cr 3.01Cr 2.95Cr 126.71Cr	47.82L 53.61L 44.56L 40.55L 76.36L 52Cr 76.92L 5.38Cr 2.09Cr 26Cr 2.01Cr 1.97Cr 85Cr
Net Debt	-1.73Cr -1.93Cr -1.61Cr -1.46Cr -2.75Cr -186.26Cr -2.78Cr -19Cr -7.56Cr -95Cr -7.26Cr -7.1Cr -305.56Cr	-2.1Cr -2.36Cr -1.96Cr -1.78Cr -3.36Cr -227.08Cr -3.38Cr -24Cr -9.21Cr -115.9Cr -8.85Cr -8.66Cr -372.54Cr

Company Profile

Eurofins Cerep specializes in the pre-clinical research of drugs for the pharmaceutical industry. Export accounts for 88.2% of net sales.

Employees

Sector

Market Cap	9.13Cr 10Cr 8.51Cr 7.74Cr 15Cr 985.59Cr 15Cr 102.77Cr 40Cr 503.03Cr 38Cr 38Cr 1.62TCr	P/E 2024 *	-	P/E 2025	-
Enterprise Value	7.03Cr 7.88Cr 6.55Cr 5.96Cr 11Cr 758.51Cr 11Cr 79Cr 31Cr 387.13Cr 30Cr 29Cr 1.24TCr	EV / Sales 2024	2.02x	EV / Sales 2025	1.67x
Free-Float	4.22%	Yield 2024 *	-	Yield 2025	-

25/08	Lotus Bakeries, the most expensive speculoos on the (stock) market in Europe
30/04	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02/25/02	Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2025	CI
30/25/30	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
03/25/03	Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
30/24/30	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2023	CI
30/23/30	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2022	CI
30/22/30	Eurofins-Cerep SA Reports Earnings Results for the Half Year Ended June 30, 2022	CI
12/22/12	Eurofins-Cerep SA Reports Earnings Results for the Full Year Ended December 31, 2021	CI
16/21/16	Global markets live: Daimler, GSK, Mattel
23/20/23	Eurofins Cerep : Launches PCR COVID-19 Self-Test In Germany, Spain	MT
24/20/24	Eurofins-Cerep Sa Reports Earnings Results for the Half Year Ended June 30, 2020	CI
30/18/30	Eurofins Cerep SA acquired KVI-Plusz.	CI

18/25/18	Eurofins Cerep : annonce ses résultats du 1er semestre 2025	PU
13/23/13	Eurofins Cerep : annonce ses résultats 2022	PU

24/09	Eurofins Cerep : annonce ses résultats du 1er semestre 2026
26/08	Lotus Bakeries, de duurste speculoos op de Europese beurs
26/08	Lotus Bakeries, la galleta más cara de la bolsa europea
25/08	Lotus Bakeries: Der teuerste Spekulatius der europäischen Börse
25/08	Lotus Bakeries, le spéculoos le plus cher de la bourse européenne

Director	Title	Age	Since
Paul Ratcliffe CHM	Chairman	-	11/08/2023
Damien Vielliard BRD	Director/Board Member	-	23/05/2024
Rodolphe Simonot BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EUROFINS-CEREP	+0.01%	+4,900.50%	-	-	10Cr
WUXI APPTEC CO., LTD.	+4.16%	+3.42%	+49.37%	+94.17%	7.43TCr
ARGENX SE	+1.87%	-2.45%	+21.74%	+76.99%	5.7TCr
LONZA GROUP AG	+2.37%	+1.16%	+6.03%	+37.72%	4.83TCr
REVOLUTION MEDICINES, INC.	+0.50%	+2.94%	+344.62%	+722.17%	4.45TCr
IQVIA HOLDINGS INC.	+3.05%	-1.80%	+28.78%	+34.51%	4.38TCr
BEONE MEDICINES AG	+1.00%	-1.46%	+5.17%	+111.90%	4.11TCr
CELLTRION, INC.	-0.54%	+2.41%	+9.31%	+58.85%	3.11TCr
WUXI BIOLOGICS (CAYMAN) INC.	+4.51%	+8.22%	+37.86%	+32.49%	2.9TCr
BIONTECH SE	+0.76%	-1.45%	-7.44%	-11.12%	2.45TCr
Average	+1.77%	-0.15%	+55.05%	+128.63%	4.37TCr
Weighted average by Cap.	+2.19%	-0.46%	+58.99%	+137.11%